Category:Tomoyoshi IMAIZUMI
Appearance
Tomoyoshi IMAIZUMI
Executive Summary
Tomoyoshi IMAIZUMI is an inventor who has filed 2 patents. Their primary areas of innovation include HETEROCYCLIC COMPOUNDS (macromolecular compounds (2 patents), Antineoplastic agents (1 patents), HETEROCYCLIC COMPOUNDS (macromolecular compounds (1 patents), and they have worked with companies such as Astellas Pharma Inc. (2 patents). Their most frequent collaborators include (2 collaborations), (2 collaborations), (2 collaborations).
Patent Filing Activity
File:Tomoyoshi IMAIZUMI Monthly Patent Applications.png
Technology Areas
File:Tomoyoshi IMAIZUMI Top Technology Areas.png
List of Technology Areas
- C07D487/08 (HETEROCYCLIC COMPOUNDS (macromolecular compounds): 2 patents
- A61P35/00 (Antineoplastic agents): 1 patents
- C07D519/00 (HETEROCYCLIC COMPOUNDS (macromolecular compounds): 1 patents
Companies
File:Tomoyoshi IMAIZUMI Top Companies.png
List of Companies
- Astellas Pharma Inc.: 2 patents
Collaborators
- Hiroki ISHIOKA (2 collaborations)
- Eiji KAWAMINAMI (2 collaborations)
- Kenichi KAWAGUCHI (2 collaborations)
- Kazuyuki KURAMOTO (2 collaborations)
- Takahiro MORIKAWA (2 collaborations)
- Hisao HAMAGUCHI (2 collaborations)
- Sunao IMADA (2 collaborations)
- Mitsuaki OKUMURA (2 collaborations)
- Takeyuki NAGASHIMA (2 collaborations)
- Tomohiro YOSHINARI (1 collaborations)
- Hideyuki WATANABE (1 collaborations)
- Kohei INAMURA (1 collaborations)
- Ryo SATO (1 collaborations)
- Yohei SEKI (1 collaborations)
- Hiroki FUKUDOME (1 collaborations)
- Ikumi KURIWAKI (1 collaborations)
Subcategories
This category has the following 6 subcategories, out of 6 total.
E
H
K
T
Categories:
- Hiroki ISHIOKA
- Eiji KAWAMINAMI
- Kenichi KAWAGUCHI
- Pages with broken file links
- Kazuyuki KURAMOTO
- Takahiro MORIKAWA
- Hisao HAMAGUCHI
- Sunao IMADA
- Mitsuaki OKUMURA
- Takeyuki NAGASHIMA
- Tomohiro YOSHINARI
- Hideyuki WATANABE
- Kohei INAMURA
- Ryo SATO
- Yohei SEKI
- Hiroki FUKUDOME
- Ikumi KURIWAKI
- Tomoyoshi IMAIZUMI
- Inventors
- Inventors filing patents with Astellas Pharma Inc.